{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:49:42Z","timestamp":1793663382885,"version":"4.5.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.japh.2023.04.029","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T02:45:35Z","timestamp":1683168335000},"page":"1044-1048","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Addressing buprenorphine bottlenecks in the context of MAT Act implementation: A shared responsibility"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2803-3747","authenticated-orcid":false,"given":"Bayla","family":"Ostrach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5958-0159","authenticated-orcid":false,"given":"Lucas","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2025-8140","authenticated-orcid":false,"given":"Delesha","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7929-6606","authenticated-orcid":false,"given":"Robin","family":"Pollini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.japh.2023.04.029_bib1","series-title":"Key substance use and mental health indicators in the United States: Results from the 2020 National Survey on Drug Use and Health (HHS Publication No. PEP21-07-01-003, NSDUH Series H-56)","year":"2021"},{"key":"10.1016\/j.japh.2023.04.029_bib2","author":"Ahmad"},{"issue":"1","key":"10.1016\/j.japh.2023.04.029_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/PRA.0000000000000437","article-title":"Availability of buprenorphine treatment in the 10 states with the highest drug overdose death rates in the United States","volume":"26","author":"Flavin","year":"2020","journal-title":"J\u00a0Psychiatr Pract"},{"issue":"10","key":"10.1016\/j.japh.2023.04.029_bib4","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2105\/AJPH.2021.306431","article-title":"Disparities in opioid overdose death trends by race\/ethnicity","volume":"111","author":"Larochelle","year":"2021","journal-title":"Am J Public Health"},{"issue":"15","key":"10.1016\/j.japh.2023.04.029_bib5","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMp2210121","article-title":"Transforming management of opioid use disorder with universal treatment","volume":"387","author":"Gupta","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.japh.2023.04.029_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.japh.2023.04.029_bib10","article-title":"The impact of the mainstreaming addiction treatment act and associated legislative action on pharmacy practice","author":"Varisco","year":"2003","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"4","key":"10.1016\/j.japh.2023.04.029_bib11","first-page":"272","article-title":"DEA disconnect leads to buprenorphine bottlenecks","volume":"15","author":"Ostrach","year":"2021","journal-title":"J\u00a0Addict Med"},{"key":"10.1016\/j.japh.2023.04.029_bib12","article-title":"Factors in rural community buprenorphine dispensing","volume":"9","author":"Major","year":"2023","journal-title":"Explor Res Clin Soc Pharm"},{"issue":"8","key":"10.1016\/j.japh.2023.04.029_bib13","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1056\/NEJMp2002908","article-title":"When prescribing isn\u2019t enough - pharmacy-level barriers to buprenorphine access","volume":"383","author":"Cooper","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.japh.2023.04.029_bib14","article-title":"Rural community pharmacist willingness to dispense Suboxone-a secret shopper investigation in South-Central Appalachia","volume":"4","author":"Trull","year":"2021","journal-title":"Explor Res Clin Soc Pharm"},{"issue":"2","key":"10.1016\/j.japh.2023.04.029_bib15","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.japh.2021.10.002","article-title":"Ensuring buprenorphine access in rural community pharmacies to prevent overdoses","volume":"62","author":"Ostrach","year":"2022","journal-title":"J\u00a0Am Pharm Assoc"},{"key":"10.1016\/j.japh.2023.04.029_bib16","series-title":"Pharmacist Stigma a Barrier to Rural Buprenorphine Access.\u201d MDEdge Psychiatry","author":"Haelle","year":"2019"},{"issue":"1","key":"10.1016\/j.japh.2023.04.029_bib17","first-page":"87","article-title":"Tracking the geographic distribution and growth of clinicians with a DEA waiver to prescribe buprenorphine to treat opioid use disorder","volume":"38","author":"Andrilla","year":"2022","journal-title":"J\u00a0Rural Health"},{"key":"10.1016\/j.japh.2023.04.029_bib18","article-title":"Patient-reported problems filling buprenorphine prescriptions and motivations for illicit use","volume":"5","author":"Winstanley","year":"2022","journal-title":"Drug Alcohol Depend Rep"},{"key":"10.1016\/j.japh.2023.04.029_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109518","article-title":"Availability of buprenorphine\/naloxone films and naloxone nasal spray in community pharmacies in 11 US states","volume":"237","author":"Hill","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.japh.2023.04.029_bib20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.japh.2022.08.017","article-title":"Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: a national survey of community-based pharmacists","volume":"63","author":"Hill","year":"2023","journal-title":"J\u00a0Am Pharm Assoc"},{"key":"10.1016\/j.japh.2023.04.029_bib22","series-title":"DEA-Registered Manufacturer and Distributor Established Controlled Substance Quantitative Thresholds and the Requirement to Report Suspicious Orders","year":"2023"},{"issue":"8","key":"10.1016\/j.japh.2023.04.029_bib23","doi-asserted-by":"crossref","first-page":"584","DOI":"10.14423\/SMJ.0000000000001433","article-title":"Eligible prescriber experiences with substance use disorder treatment and perceptions of pharmacy barriers to buprenorphine","volume":"115","author":"Harless","year":"2022","journal-title":"South Med J"},{"issue":"5","key":"10.1016\/j.japh.2023.04.029_bib24","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.japh.2022.04.019","article-title":"North Carolina community pharmacists\u2019 buprenorphine dispensing practices and attitudes","volume":"62","author":"Carpenter","year":"2022","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"6","key":"10.1016\/j.japh.2023.04.029_bib25","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/add.15314","article-title":"Availability of buprenorphine\/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA","volume":"116","author":"Hill","year":"2021","journal-title":"Addiction"},{"key":"10.1016\/j.japh.2023.04.029_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102701","article-title":"Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: a case study of the rural risk environment in Appalachian Kentucky","volume":"85","author":"Cooper","year":"2020","journal-title":"Int J Drug Policy"},{"issue":"6","key":"10.1016\/j.japh.2023.04.029_bib27","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.japh.2022.07.003","article-title":"Access to community pharmacies: a nationwide geographic information systems cross-sectional analysis","volume":"62","author":"Berenbrok","year":"2022","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"key":"10.1016\/j.japh.2023.04.029_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103703","article-title":"\u201cRed Flags\u201d and \u201cRed Tape\u201d: telehealth and pharmacy-level barriers to buprenorphine in the United States","volume":"105","author":"Textor","year":"2022","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.japh.2023.04.029_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108729","article-title":"Pharmacy-related buprenorphine access barriers: an audit of pharmacies in counties with a high opioid overdose burden","volume":"224","author":"Kazerouni","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"10.1016\/j.japh.2023.04.029_bib30","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.japh.2021.04.014","article-title":"Switching pharmacies leads to gaps in medication possession in individuals treated with buprenorphine","volume":"61","author":"Varisco","year":"2021","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"10","key":"10.1016\/j.japh.2023.04.029_bib31","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1176\/appi.ajp.21111141","article-title":"Impact of COVID-19 telehealth policy changes on buprenorphine treatment for opioid use disorder","volume":"179","author":"Lin","year":"2022","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.japh.2023.04.029_bib32","first-page":"467","article-title":"An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic","volume":"37","author":"Hughes","year":"2021","journal-title":"J\u00a0Rural Health. Published online March 15"},{"key":"10.1016\/j.japh.2023.04.029_bib33","author":"Drug Enforcement Administration"},{"key":"10.1016\/j.japh.2023.04.029_bib41","series-title":"DEA, SAMHSA Extend COVID-19 Telemedicine Flexibilities for Prescribing Controlled Medications for Six Months While Considering Comments from the Public","year":"2023"},{"issue":"2","key":"10.1016\/j.japh.2023.04.029_bib34","first-page":"93","article-title":"Buprenorphine pharmacology review: update on transmucosal and long-acting formulations","volume":"13","author":"Coe","year":"2019","journal-title":"J\u00a0Addict Med"},{"issue":"8","key":"10.1016\/j.japh.2023.04.029_bib35","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.2839","article-title":"Federal and state pharmacy regulations and dispensing barriers to buprenorphine access at retail pharmacies in the US","volume":"3","author":"Qato","year":"2022","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.japh.2023.04.029_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102722","article-title":"Unintentional drug overdose: is more frequent use of non-prescribed buprenorphine associated with lower risk of overdose?","volume":"79","author":"Carlson","year":"2020","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.japh.2023.04.029_bib37","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jsat.2019.07.005","article-title":"Buprenorphine in the United States: motives for abuse, misuse, and diversion","volume":"104","author":"Chilcoat","year":"2019","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"1","key":"10.1016\/j.japh.2023.04.029_bib38","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1080\/08897077.2021.1942395","article-title":"Alternative use of buprenorphine among people who use opioids in three US Cities","volume":"43","author":"Gandhi","year":"2022","journal-title":"Subst Abus"},{"key":"10.1016\/j.japh.2023.04.029_bib39","series-title":"B.U.P.E. - Buprenorphine Understanding in the Pharmacy Environment","author":"Ostrach","year":"2021"},{"key":"10.1016\/j.japh.2023.04.029_bib40","article-title":"A\u00a0content review of buprenorphine training programs for pharmacists","volume":"6","author":"Davis","year":"2022","journal-title":"Explor Res Clin Soc Pharm"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319123001401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319123001401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:51:59Z","timestamp":1761544319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319123001401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1544319123001401"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2023.04.029","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Addressing buprenorphine bottlenecks in the context of MAT Act implementation: A shared responsibility","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2023.04.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}